Under 10% of people eligible to benefit from obesity jabs such as Wegovy have access to them, warns the World Health Organization as it publishes its initial advice on the therapies.
Given in excess of 1,000,000,000 people worldwide currently living with obesity, it is calling for increased and just availability to GLP-1 medication.
Per estimates, more than two billion could be living with obesity by 2030 if no action is taken.
"Our latest guidelines acknowledges that excess weight is a chronic disease that can be treated with thorough and lifelong treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are significant hurdles to universal availability to the treatments that can assist patients in reducing considerable weight, explains the agency.
Skinny Jab Scarcity
Even under the present most optimistic scenario, the supply of such drugs could only cover approximately 100 million people – less than 10% of the global need, per the WHO.
The guideline encourages nations and manufacturers to expand availability, via strategies like licensing agreements.
The intellectual property rights on a key compound – the main ingredient of the drug Wegovy – is scheduled to end in several countries in 2026.
The Way Obesity Injections Function
The injections replicate a natural hormone to delay gastric emptying, reduce hunger and increase feelings of fullness so people reduce food intake.
People commonly begin shedding pounds within a few weeks of beginning the weekly injections.
Evidence indicates patients may regain a significant portion within a year of stopping the treatment, because their normal appetite resume.
To be carrying excess weight increases your risk for developing diseases, such as diabetes, cardiovascular issues, stroke, and some malignancies.
Excess weight impacts people in all nations and was linked to 3.7 million deaths worldwide in 2024, as per the WHO.
